References
- Ogbogu PU, Bochner BS, Butterfield JH, . Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009;121:1319–1325.
- Cools J, De Angelo DJ, Gotlib J, . A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Eng J Med 2003;348:1201–1214.
- Helbig G, Moskwa A, Hus M, . Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study. Hematol Oncol 2010;28:93–97.
- Helbig G, Moskwa A, Hus M, . Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Cancer Chemother Pharmacol 2011; 67:967–969.
- Pardanani A, D’Souza A, Knudson RA, . Long-term follow-up of FIP1L1-PDGFRA mutated patients with eosinophilia: survival and clinical outcome. Leukemia 2012 Jun 18. [Epub ahead of print].
- Baccarani M, Cilloni D, Rondoni M, . The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRA positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007;92:1173–1179.
- Metzgeroth G, Walz C, Erben P, . Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome - a phase II study. Br J Haematol 2008;143:707–715.
- Vandenberghe P, Wlodarska I, Michaux I, . Clinical and molecular features of FIP1L1-PDGFRA (+) chronic eosinophilic leukemias. Leukemia 2004;18:734–742.
- Klion AD. Eosinophilic myeloproliferative disorders. Hematology Am Soc Hematol Educ Program 2011:257–263.
- Roufosse F. Hypereosinophilic syndrome variants: diagnostic and therapeutic considerations. Haematologica 2009;94:1188–1193
- Klion AD, Noel P, Akin C, . Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis and imatinib responsiveness. Blood 2003;101: 4460–4666.
- Robyn J, Lemery S, McCoy JP, . Multilineage involvement of the fusion gene in patients with FIP1L1-PDGFRA-positive hypereosinophilic syndrome. Br J Haematol 2006;132:286–292.
- Galimberti S, Ciabatti E, Ottimo F, . Cell clonality in hypereosinophilic syndrome: what pathogenic role?Clin Exp Rheumatol 2007;25:17–22.
- Klion AD, Robyn J, Maric I, . Relapse following discontinuation of imatinib mesylate therapy for FIP1L1-PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood 2007;110:3552–3556.
- Mahon FX, Rea D, Guilhot J, . Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11: 1029–1035.